XML 53 R16.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Segments of Business and Geographic Areas | 9 Months Ended
--- | ---
Sep. 27, 2015
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 1,277 |  |  | 1,173 |  |  | 8.9 | %
International |  | 2,037 |  |  | 2,416 |  |  | (15.7 | )
Total |  | 3,314 |  |  | 3,589 |  |  | (7.7 | )
Pharmaceutical |  |  |  |  |  |
United States |  | 4,509 |  |  | 4,723 |  |  | (4.5 | )
International |  | 3,185 |  |  | 3,584 |  |  | (11.1 | )
Total |  | 7,694 |  |  | 8,307 |  |  | (7.4 | )
Medical Devices |  |  |  |  |  |
United States |  | 3,005 |  |  | 2,946 |  |  | 2.0 |
International |  | 3,089 |  |  | 3,625 |  |  | (14.8 | )
Total |  | 6,094 |  |  | 6,571 |  |  | (7.3 | )
Worldwide |  |  |  |  |  |
United States |  | 8,791 |  |  | 8,842 |  |  | (0.6 | )
International |  | 8,311 |  |  | 9,625 |  |  | (13.7 | )
Total |  | $ | 17,102 |  |  | 18,467 |  |  | (7.4 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 3,991 |  |  | 3,802 |  |  | 5.0 | %
International |  | 6,196 |  |  | 7,088 |  |  | (12.6 | )
Total |  | 10,187 |  |  | 10,890 |  |  | (6.5 | )
Pharmaceutical |  |  |  |  |  |
United States |  | 13,423 |  |  | 13,076 |  |  | 2.7 |
International |  | 9,943 |  |  | 11,238 |  |  | (11.5 | )
Total |  | 23,366 |  |  | 24,314 |  |  | (3.9 | )
Medical Devices |  |  |  |  |  |
United States |  | 8,980 |  |  | 9,300 |  |  | (3.4 | )
International |  | 9,730 |  |  | 11,573 |  |  | (15.9 | )
Total |  | 18,710 |  |  | 20,873 |  |  | (10.4 | )
Worldwide |  |  |  |  |  |
United States |  | 26,394 |  |  | 26,178 |  |  | 0.8 |
International |  | 25,869 |  |  | 29,899 |  |  | (13.5 | )
Total |  | $ | 52,263 |  |  | 56,077 |  |  | (6.8 | )%
SEGMENT PRE-TAX PROFIT
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer (1) |  | $ | 811 |  |  | 407 |  |  | 99.3 | %
Pharmaceutical(2) |  | 2,732 |  |  | 3,247 |  |  | (15.9 | )
Medical Devices(3) |  | 835 |  |  | 3,399 |  |  | (75.4 | )
Segments operating profit |  | 4,378 |  |  | 7,053 |  |  | (37.9 | )
Less: Expense not allocated to segments (4) |  | 256 |  |  | 243 |  |  |
Worldwide income before taxes |  | $ | 4,122 |  |  | 6,810 |  |  | (39.5 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer (1) |  | $ | 1,772 |  |  | 1,588 |  |  | 11.6 | %
Pharmaceutical(2) |  | 9,816 |  |  | 9,921 |  |  | (1.1 | )
Medical Devices(3) |  | 4,640 |  |  | 7,069 |  |  | (34.4 | )
Segments operating profit |  | 16,228 |  |  | 18,578 |  |  | (12.6 | )
Less: Expense not allocated to segments (4) |  | 790 |  |  | 718 |  |  |
Worldwide income before taxes |  | $ | 15,438 |  |  | 17,860 |  |  | (13.6 | )%
(1) Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014. (2) Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014. (3) Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASR TM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal nine months of 2014. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
United States |  | $ | 8,791 |  |  | 8,842 |  |  | (0.6 | )%
Europe |  | 3,802 |  |  | 4,446 |  |  | (14.5 | )
Western Hemisphere, excluding U.S. |  | 1,463 |  |  | 1,820 |  |  | (19.6 | )
Asia-Pacific, Africa |  | 3,046 |  |  | 3,359 |  |  | (9.3 | )
Total |  | $ | 17,102 |  |  | 18,467 |  |  | (7.4 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
United States |  | $ | 26,394 |  |  | 26,178 |  |  | 0.8 | %
Europe |  | 11,993 |  |  | 14,387 |  |  | (16.6 | )
Western Hemisphere, excluding U.S. |  | 4,603 |  |  | 5,378 |  |  | (14.4 | )
Asia-Pacific, Africa |  | 9,273 |  |  | 10,134 |  |  | (8.5 | )
Total |  | $ | 52,263 |  |  | 56,077 |  |  | (6.8 | )%

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration